Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Breast Neoplasms -- drug therapy -- metabolism"" wg kryterium: Temat


Tytuł :
Uloga inhibitora CDK4/6 u liječenju hormonski ovisnoga metastatskog raka dojke negativnog na HER-2
Index Terms :
TUMORI DOJKE – farmakoterapija, metabolizam, patologija, smrtnost; HORMONSKI OVISNI TUMORI – farmakoterapija, metabolizam, patologija, smrtnost; PROTUTUMORSKI LIJEKOVI – farmakologija, neželjeni učinci, terapijska primjena; RECEPTOR ERBB-2 – metabolizam; CIKLIN OVISNA KINAZA 4 – antagonisti i inhibitori, metabolizam; CIKLIN OVISNA KINAZA 6 – antagonisti i inhibitori, metabolizam; AROMATOZNI INHIBITORI – terapijska primjena; FULVESTRANT – terapijska primjena; INHIBITORI PROTEINSKE KINAZE – neželjeni učinci, terapijska primjena; TUMORSKE METASTAZE; PREŽIVLJENJE BEZ PROGRESIJE BOLESTI
BREAST NEOPLASMSdrug therapy, metabolism, mortality, pathology; NEOPLASMS, HORMONE-DEPENDENT – drug therapy, metabolism, mortality, pathology; ANTINEOPLASTIC AGENTS – adverse effects, pharmacology, therapeutic use; RECEPTOR, ERBB-2 – metabolism; CYCLIN-DEPENDENT KINASE 4 – antagonists and inhibitors, metabolism; CYCLIN-DEPENDENT KINASE 6 – antagonists and inhibitors, metabolism; AROMATOZNI INHIBITORI – therapeutic use; FULVESTRANT – therapeutic use; PROTEIN KINASE INHIBITORS – adverse effects, therapeutic use; NEOPLASM METASTASIS; PROGRESSION-FREE SURVIVAL
text
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Tytuły dodatkowe :
Role of CDK4/6 inhibitors in metastatic hormon positive HER2 negative breast cancer treatment
URL :
info:eu-repo/semantics/altIdentifier/doi/10.26800/LV-141-1-2-6
Zasób elektroniczny
Tytuł :
Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.
Index Terms :
Cancérologie
Sciences bio-médicales et agricoles
Médecine pathologie humaine
Animals
Antineoplastic Combined Chemotherapy Protocols -- pharmacology
Biomarkers, Tumor -- metabolism
Breast Neoplasms -- drug therapy -- metabolism
Cell Line, Tumor
Chemotherapy, Adjuvant -- methods
Doxorubicin -- pharmacology
Epirubicin -- pharmacology
Female
Humans
Interferon Regulatory Factor-7 -- metabolism
Interferon Type I -- metabolism
Interferon-beta -- metabolism
Methotrexate -- pharmacology
Mice
Mice, Inbred BALB C
Mice, Inbred NOD
Mice, Nude
Mice, SCID
Neoadjuvant Therapy -- methods
Neoplasm Recurrence, Local -- metabolism
Receptor, ErbB-2 -- metabolism
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283375">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/283375
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Differential effects of superoxide dismutase and superoxide dismutase/catalase mimetics on human breast cancer cells
Index Terms :
Antioxidants/*pharmacology
Breast Neoplasms/drug therapy/*metabolism
Cell Adhesion/drug effects
Cell Line
Cell Movement/drug effects
Cell Proliferation/drug effects
Female
Humans
Hydrogen Peroxide/*metabolism
MCF-7 Cells
Metalloporphyrins/*pharmacology
NF-kappa B/metabolism
Organometallic Compounds/*pharmacology
Salicylates/*pharmacology
Signal Transduction/drug effects
Superoxides/*metabolism
Tumor
Contribution to Journal
URL :
DOI:10.1007/s10549-015-3329-z
Shah, Manisha, Liu, Guei-Sheung (Rick), Thompson, Rik, Dusting, Gregory, & Peshavariya, Hitesh (2015) Differential effects of superoxide dismutase and superoxide dismutase/catalase mimetics on human breast cancer cells. Breast Cancer Research and Treatment, 150(3), pp. 523-534.
Zasób elektroniczny
Tytuł :
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy
Index Terms :
Chirurgie
Adult
Aged
Antibiotics, Antineoplastic -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Axilla
Breast Neoplasms -- drug therapy -- metabolism -- pathology
Carcinoma, Ductal, Breast -- drug therapy -- metabolism -- pathology
Carcinoma, Lobular -- drug therapy -- metabolism -- pathology
Chemotherapy, Adjuvant
Cisplatin -- therapeutic use
Disease-Free Survival
Epirubicin -- therapeutic use
Female
Fluorouracil -- therapeutic use
Humans
Lymph Nodes -- metabolism -- pathology
Methotrexate -- therapeutic use
Middle Aged
Prognosis
Proto-Oncogene Proteins c-bcl-2 -- metabolism
Retrospective Studies
Treatment Outcome
Tumor Markers, Biological -- metabolism
Tumor Suppressor Protein p53 -- metabolism
BCL2
Biomarkers
Breast cancer
Expression
TP53
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/187913">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/187913
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: A landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
Index Terms :
Hématologie
Cancérologie
Adult
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- mortality
Carcinoma, Ductal, Breast -- drug therapy -- metabolism -- mortality
Chemotherapy, Adjuvant -- mortality
Disease-Free Survival
Female
Humans
Middle Aged
Neoadjuvant Therapy -- mortality
Prognosis
Proportional Hazards Models
Treatment Outcome
Tumor Suppressor Protein p53 -- biosynthesis
Breast cancer
Landmark analysis
Neoadjuvant chemotherapy
Pathological complete response
TP53
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/194676">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/194676
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Index Terms :
Cancérologie
Administration, Oral
Adult
Aged
Antibodies, Monoclonal, Humanized -- adverse effects -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
Chemotherapy, Adjuvant
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Infusions, Intravenous
Maximum Tolerated Dose
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness -- pathology
Neoplasm Staging
Quinazolines -- adverse effects -- therapeutic use
Receptor, ErbB-2 -- metabolism
Survival Analysis
Treatment Outcome
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/186935">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/186935
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
Index Terms :
Cancérologie
Adult
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- pathology
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Quinolines -- administration & dosage -- adverse effects -- therapeutic use
Receptor, ErbB-2 -- metabolism
Vinblastine -- administration & dosage -- adverse effects -- analogs & derivatives -- therapeutic use
Breast cancer
HER2
Neratinib
Tyrosine kinase inhibitor
Vinorelbine
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/144320">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/144320
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Index Terms :
Cancérologie
Médecine pathologie humaine
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- pharmacology -- therapeutic use
Brain Neoplasms -- drug therapy -- metabolism -- mortality -- secondary
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
Dacarbazine -- administration & dosage -- analogs & derivatives
Disease-Free Survival
Female
Humans
Maximum Tolerated Dose
Middle Aged
Quinazolines -- administration & dosage
Receptor, ErbB-2 -- metabolism
Treatment Outcome
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/157834">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/157834
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.
Index Terms :
Cancérologie
Médecine pathologie humaine
Sciences bio-médicales et agricoles
Antigens, Neoplasm -- genetics -- metabolism
Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- mortality
Cell Nucleus -- metabolism
Cytoplasm -- metabolism
DNA Topoisomerases, Type II -- genetics -- metabolism
DNA-Binding Proteins -- genetics -- metabolism
Epirubicin -- therapeutic use
Female
Humans
Immunohistochemistry
Neoadjuvant Therapy
Prognosis
Protein Transport
Topoisomerase II Inhibitors -- therapeutic use
anthracyclines
biomarker
breast cancer
quantitative immunofluorescence
TOP2A
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/153435">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/153435
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
Index Terms :
Cancérologie
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- pathology
Deoxycytidine -- administration & dosage -- adverse effects -- analogs & derivatives
Diarrhea -- chemically induced
Disease-Free Survival
Drug Administration Schedule
Female
Fluorouracil -- administration & dosage -- adverse effects -- analogs & derivatives
Humans
Kaplan-Meier Estimate
Middle Aged
Nausea -- chemically induced
Quinazolines -- administration & dosage -- adverse effects
Quinolines -- adverse effects -- therapeutic use
Receptor, ErbB-2 -- metabolism
Treatment Outcome
Vomiting -- chemically induced
Breast
phase II
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/168190">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/168190
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
Index Terms :
Sciences bio-médicales et agricoles
Adult
Aged
Antibodies, Monoclonal, Humanized -- administration & dosage -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
Cisplatin -- administration & dosage -- adverse effects
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Maximum Tolerated Dose
Middle Aged
Multivariate Analysis
Neoplasm Invasiveness -- pathology
Neoplasm Staging
Prognosis
Proportional Hazards Models
Receptor, Epidermal Growth Factor -- drug effects -- metabolism
Receptors, Estrogen -- drug effects -- metabolism
Receptors, Progesterone -- drug effects -- metabolism
Risk Assessment
Survival Analysis
Treatment Outcome
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/199116">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/199116
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Index Terms :
Cancérologie
Aged
Aged, 80 and over
Androstadienes -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
Female
Follow-Up Studies
Humans
International Agencies
Neoplasm Metastasis
Neoplasm Recurrence, Local -- drug therapy -- pathology
Neoplasm Staging
Prognosis
Receptor, ErbB-2 -- metabolism
Receptors, Estrogen -- metabolism
Receptors, Progesterone -- metabolism
Safety
Sirolimus -- administration & dosage -- analogs & derivatives
Survival Rate
Advanced breast cancer
Endocrine resistance
Geriatric
Progression-free survival
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/195356">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/195356
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Health-related quality of life and disease symptoms in postmenopausal women with hr+, her2- advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy
Index Terms :
Sciences bio-médicales et agricoles
Adult
Aged
Androstadienes -- adverse effects -- therapeutic use
Antineoplastic Agents -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism
Disease Progression
Disease-Free Survival
Female
Health Status
Humans
Immunosuppressive Agents -- therapeutic use
Middle Aged
Placebos -- therapeutic use
Quality of Life
Questionnaires
Receptor, ErbB-2 -- metabolism
Receptors, Estrogen -- metabolism
Receptors, Progesterone -- metabolism
Sirolimus -- adverse effects -- analogs & derivatives -- therapeutic use
Treatment Outcome
Advanced breast cancer
Everolimus
Exemestane
Health-related quality of life
Hormone receptor positive
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/195350">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/195350
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding?
Index Terms :
Sciences bio-médicales et agricoles
Antiemetics -- adverse effects -- pharmacokinetics
Antineoplastic Agents -- adverse effects -- pharmacokinetics
Breast Feeding
Breast Neoplasms -- drug therapy -- metabolism
Drug-Related Side Effects and Adverse Reactions -- chemically induced
Female
Humans
Infant, Newborn
Intercellular Signaling Peptides and Proteins -- adverse effects -- pharmacokinetics
Lactation -- metabolism
Male
Milk, Human -- metabolism
Pregnancy
Pregnancy Complications, Neoplastic -- drug therapy -- metabolism
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/200244">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/200244
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Pertuzumab: new hope for patients with HER2-positive breast cancer.
Index Terms :
Cancérologie
Antibodies, Monoclonal, Humanized -- adverse effects -- pharmacology -- therapeutic use
Antineoplastic Agents -- adverse effects -- pharmacology -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism
Dimerization
Disease-Free Survival
Female
Humans
Receptor, ErbB-2 -- immunology -- metabolism
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/135471">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/135471
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny
Tytuł :
Targeting the subtypes of breast cancer: rethinking investigational drugs.
Index Terms :
Cancérologie
Breast Neoplasms -- drug therapy -- metabolism
Drugs, Investigational -- therapeutic use
Female
Humans
Receptor, erbB-2 -- metabolism
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/148651">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/148651
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Zasób elektroniczny

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies